Generic Name: risperidone
Brand Name: Perseris
Manufacturer: HLS Therapeutics Inc.
Therapeutic Area: Schizophrenia, adults
Indications: Treatment of schizophrenia in adults.
Manufacturer Requested Reimbursement Criteria1: Treatment of schizophrenia in adults.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: December 24, 2020
Call for patient/clinician input closed: February 22, 2021
Anticipated Date: January 29, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.